




RealRate

SEMICONDUCTORS 2017

Intermolecular INC
Rank 26 of 78





SEMICONDUCTORS 2017

Intermolecular INC
Rank 26 of 78



The relative strengths and weaknesses of Intermolecular INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intermolecular INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Intermolecular INC is the variable Research and Development, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 291%, being 38% points above the market average of 254%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Amortization of Intangible Assets | 0 |
| Assets, Current | 32,254 |
| Assets, Non-Current | 597 |
| Intangible Assets | 4,001 |
| Liabilities, Current | 4,956 |
| Liabilities, Non-Current | 67 |
| Other Assets | 5,352 |
| Other Compr. Net Income | -8.0 |
| Other Expenses | 16,951 |
| Other Liabilities | 3,149 |
| Other Net Income | 438 |
| Other Revenues | 47,298 |
| Property, Plant and Equipment | 10,964 |
| Research and Development | 28,126 |
| Selling, General and Administrative Expense | 18,096 |

| Output Variable | Value in 1000 USD |
|-----------------------------|-------------------|
| Liabilities | 8,172 |
| Assets | 53,168 |
| Expenses | 63,173 |
| Revenues | 47,298 |
| Stockholders Equity | 44,996 |
| Net Income | -15,437 |
| Comprehensive Net Income | -15,445 |
| BaseVar | 86,128 |
| ECR before LimitedLiability | 271% |
| Economic Capital Ratio | 291% |